Insulet ($PODD) announced an update on their ongoing clinical study. Study Overview: Insulet Corporation is running a new clinical study titled ...

Insulet delivered third-quarter revenue growth of 25% in constant currency and pushed up gross margin by 150 basis points after a savvy decision to consolidate all pumps to the Omnipod 5 platform. Why ...

Insulet ($PODD) announced an update on their ongoing clinical study. Study Overview Insulet’s new study, officially titled “Safety and Efficacy of ...

OAKVILLE, ON, April 7, 2025 /CNW/ - Insulet Corporation (PODD), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that Omnipod 5 is now ...

Insulet PODD delivered outstanding first-quarter performance, fueled by the rollout of the new Omnipod 5, which has been on fire since regulatory approval was received last fall. Though management ...

Insulet Corporation (NASDAQ:PODD) reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the consensus of $414.383 million. Total Omnipod revenue of $422 million marked ...

Just a few weeks into the full-scale rollout of its Omnipod 5 insulin pump, Insulet has gotten the green light to expand the device’s reach even further. When the FDA originally cleared the automated, ...

Insulet Corporation saw a significant drop in stock price in 2023 due to concerns over the impact of GLP-1 weight loss drugs on the insulin pump industry. These fears seem to be largely overblown, ...

As Americans flock to nearby orchards for festive bouts of autumn apple picking, Insulet is celebrating a particularly bountiful stateside Apple harvest itself. The diabetes devicemaker has earned FDA ...

As a child with Type 1 diabetes, Arden Benner of Robbinsville, New Jersey, has gotten used to needle sticks and injections. Scott Benner, her father, says, "21 injections every 3 days, plus her finger ...

Insulet Presents Pivotal Extension Data for Preschool Children and Other Omnipod® 5 System Clinical Research at American Diabetes Association 82nd Scientific Sessions ACTON, Mass.--(BUSINESS WIRE)-- ...

The Omnipod 5 will be immediately available for people ages 6 to 70. A new technology for people with Type 1 diabetes, one that has been nearly a decade in the making, has been approved by the U.S.